STOCK TITAN

Amgen Appoints Amy E. Miles To Board Of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Amgen has appointed Amy E. Miles to its Board of Directors, effective July 23, 2020. Ms. Miles brings extensive experience, having served as the CEO and chair of Regal Entertainment Group. With this appointment, Amgen's Board consists of 12 directors, 11 of whom are independent. Robert A. Bradway, Amgen's chairman and CEO, expressed confidence in Miles' ability to contribute value to the company. Her previous roles include board positions at Norfolk Southern Corporation and Gap Inc., suggesting a strong governance background.

Positive
  • Appointment of an experienced leader in Amy E. Miles, enhancing board diversity and expertise.
  • Strengthened governance with 11 out of 12 directors being independent.
Negative
  • Potential gaps in industry-specific experience as Miles comes from entertainment rather than biotech.

THOUSAND OAKS, Calif., July 23, 2020 /PRNewswire/ -- Amgen today announced the appointment of Amy E. Miles to its Board of Directors, effective July 23, 2020.  Ms. Miles will serve as a member of the Board's Audit Committee and Governance and Nominating Committee.  Following the appointment of Ms. Miles, the Board will be composed of 12 directors, 11 of whom are independent.

"Amy is an accomplished business leader and an experienced public company board member," said Robert A. Bradway, chairman and chief executive office of Amgen. "We are confident that she will add great value to Amgen and our Board of Directors."

Ms. Miles is the former chair of the board (from 2015 to 2018) and chief executive officer (from 2009 to 2018) of Regal Entertainment Group, Inc. Ms. Miles also served as chief executive officer of Regal Cinemas, Inc. from 2009 to 2018.  Prior to this, Ms. Miles served as executive vice president, chief financial officer and treasurer, Regal Entertainment Group from 2002 to 2009.  She also served as the executive vice president, chief financial officer and treasurer of Regal Cinemas from 2000 to 2009.  Ms. Miles joined Regal Cinemas in 1999 as Senior Vice President of Finance.  Previously, Ms. Miles was with Deloitte & Touche, LLP and PricewaterhouseCoopers LLP.

Ms. Miles has been a director of Norfolk Southern Corporation, a transportation company, since 2014 and serves on the Executive Committee, Governance and Nominating Committee, and chairs the Audit Committee.  Ms. Miles has been a director of Gap Inc., an apparel retail company, since 2020 and serves on the Audit and Finance Committee.  Ms. Miles was a director of National CineMedia, Inc., a cinema advertising company, from 2011 to 2015.  She was a director of Townsquare Media, Inc., a radio, digital media, entertainment, and digital marketing solutions company, from 2014 until 2016.

Ms. Miles has been a director of ASM Global, a privately-held entertainment and venue management company, since 2019.  Ms. Miles serves on the boards of trustees of the University of Tennessee and the Boys and Girls Club of Eastern Tennessee.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Trish Rowland, 805-447-5631 (media)
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors)

"Amgen

 

"Cision" View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-appoints-amy-e-miles-to-board-of-directors-301099042.html

SOURCE Amgen

FAQ

Who is Amy E. Miles and what is her role at Amgen?

Amy E. Miles has been appointed to Amgen's Board of Directors and will serve on the Audit Committee and Governance and Nominating Committee.

When was Amy E. Miles appointed to Amgen's Board?

Amy E. Miles was appointed to Amgen's Board of Directors on July 23, 2020.

What is the significance of Amy E. Miles' appointment to Amgen?

Her appointment is significant as it enhances the board's expertise and governance structure, with a majority of independent directors.

How many directors are there on Amgen's Board after the appointment of Amy E. Miles?

After her appointment, Amgen's Board consists of 12 directors, with 11 being independent.

Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Stock Data

150.64B
536.44M
0.25%
81.23%
1.74%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS